Karachi: SEARLE Pharmaceutical signed a licensing and marketing agreement with Beximco Pharmaceutical of Bangladesh to produce and sale COVID-19 medicine Remdesivir.
“Searl is planning to import Remdesvir from Bangladesh to meet Pakistan’s demand,” said Hammad Akram , researcher at Topline Research. After completing all legal procedures, company will start manufacturing this medicine in Pakistan.
Ferozsons Laboratories through its subsidiary BF Biosciences has successfully concluded non-exclusive license agreement with Gilead Sciences for the manufacturing of the same drug.
Be the first to comment